



Oslo Cancer Cluster Invites you to join

Cancer Crosslinks 2024

January 25, 2024

Bridging innovations to improve clinical outcomes for cancer patients

You are invited to join distinguished speakers from Germany, France, UK & USA as they address emerging diagnostic and treatment options for solid and hematological cancers.

Date & Time To Register

Thursday, January 25, 2024 at Oslo Cancer Cluster Innovation Park

10:30 - 16:15 Daytime Education Event (with digital option)

16:15+ Networking Event (on site)

REGISTER at: cancercrosslinks.com

Speakers & Topics

- **Sonja Loges**, Dept of Personalized Oncology, DKFZ-Hector Cancer Institute & Division of Personalized Medical Oncology, University Medical Centre Mannheim, Heidelberg University, Germany
Opening keynote
- **Lisa Derosa**, Tumour Immunology and Immunotherapy of Cancer Unit, Institut Gustave Roussy, Paris, France
Microbiota-centered interventions and cancer immunotherapy: recent learnings and clinical implications
- **Leo Rasche**, University Hospital Würzburg, Mildred Scheel Nachwuchszentrum (MSNZ) for Cancer Research, Germany
Tumor heterogeneity in multiple myeloma: clinical consequences?
- **Raza Ali**, Cancer Research UK, Cambridge Institute, University of Cambridge, UK
Highly multiplexed imaging for precision breast immuno-oncology
- **Paolo Tarantino**, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Antibody-drug conjugates: a pan-histologic revolution in the treatment of cancer.
- **Mihaela van der Schaar**, Cambridge Center for AI in Medicine, University of Cambridge, UK
AI-enabled personalized medicine (tbc)

Moderators from Norway

- **Vilde Drageset Haakensen**, Oslo University Hospital
- **Marte Grønlie Cameron**, Sørlandet Hospital, Kristiansand
- **Fredrik Schjesvold**, Oslo University Hospital
- **Katrin Kleinmanns**, University of Bergen

A limited number of domestic travel tickets are available for clinicians and researchers.

Please contact: cwh@oslocancercluster.no

For more information, please contact the organizing team at cancercrosslinks.com

Project: Charlotte Homme or Dave Tippett. **Scientific:** Jutta Heix or Marine Jeanmougin

Register here: cancercrosslinks.com

Sponsored by:



Program

16th Cancer Crosslinks 2024

Thursday, January 25, 2024; Oslo Cancer Cluster Innovation Park, Ullernchausséen 64 – 66, 0379 Oslo

Bridging innovations to improve clinical outcomes for cancer patients	
From 10:00	Registration on-site & Log-in for live-stream
10:30 - 10:45	Opening and welcome , Oslo Cancer Cluster
10:45 - 10:50	SESSION 1 - EXPLORING THE FUTURE OF CANCER IMMUNOTHERAPY
Moderators	Vilde Drageset Haakensen , Senior Consultant Oncologist and Head of Lung Cancer Research, Dept of Oncology & Project group leader, Dept of Cancer Genetics, Oslo University Hospital, Norway. Marte Grønlie Cameron , Clinical Oncologist, Palliative Care Unit and Head of Research at the Center for Cancer Treatment, Sørlandet Hospital, Kristiansand, Norway.
10:50 - 11:35	Opening keynote address Sonja Loges , Professor, Director, Dept of Personalized Oncology, DKFZ-Hector Cancer Institute & Division of Personalized Medical Oncology, University Medical Centre Mannheim, Heidelberg University, Germany.
11:35 - 12:15	Microbiota-centered interventions and cancer immunotherapy: recent learnings and clinical implications Lisa Derosa , Immuno-Oncologist, Associate Professor, Tumour immunology and immunotherapy of cancer unit, Zitvogel Lab, Institut Gustave Roussy, Paris, France.
12:15 - 13:00	Lunch Break
13:00 - 13:05	SESSION 2 – IMPACTS ON CLINICAL OUTCOMES BY TARGETING TUMOR HETEROGENEITY
Moderators	Fredrik Schjesvold , Leader of Oslo Myeloma Center, Dept of Haematology, Oslo University Hospital, Norway. Head of the Norwegian Myeloma Association, President of the Nordic Myeloma Study Group and board member of the European Myeloma Network. Katrin Kleinmanns , Researcher, Precision Oncology Lab (PrecOS), Innovative Novel Ovarian cancer treatment approaches (INOVA) group, University of Bergen, Norway.
13:05 - 13:45	Tumor heterogeneity in multiple myeloma: clinical consequences? Leo Rasche , Senior physician, Specialist in Internal Medicine, Haematology and Oncology, University Hospital Würzburg, Junior Group Leader, Mildred Scheel Nachwuchszenrum (MSNZ) for Cancer Research, Germany.
13:45 - 14:20	Highly multiplexed imaging for precision breast immuno-oncology Raza Ali , Group Leader, Systems Cancer Pathology Lab, Honorary Consultant Pathologist, Cancer Research UK Cambridge Institute, University of Cambridge, UK.
14:20 - 14:50	Coffee break
14:50 - 14:55	SESSION 3 - EMERGING PLATFORMS FOR CANCER TREATMENT DELIVERY
Moderators	Vilde Drageset Haakensen , Senior Consultant Oncologist and Head of Lung Cancer Research, Dept of Oncology & Project group leader, Dept of Cancer Genetics, Oslo University Hospital, Norway. Marte Grønlie Cameron , Clinical Oncologist, Palliative Care Unit and Head of Research at the Center for Cancer Treatment, Sørlandet Hospital, Kristiansand, Norway.
14:55 - 15:35	Antibody-drug conjugates: a pan-histologic revolution in the treatment of cancer. Paolo Tarantino , Advanced Research Fellow at Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
15:35 - 16:05	AI-enabled personalized medicine (tbc) Mihaela van der Schaar , John Humphrey Plummer Professor of Machine Learning, AI, and Medicine. Director, Cambridge Center for AI in Medicine, University of Cambridge, UK.
16:05 - 16:15	Closing remarks
From 16:15	An invitation to join the afternoon networking event.